{"DataElement":{"publicId":"62334","version":"4","preferredName":"Gynecologic Tumor Histologic Category","preferredDefinition":"the structural pattern of cancer cells used to define a diagnosis.","longName":"GYN_TUMOR_HIST_CAT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2190065","version":"1","preferredName":"Gynecologic Tumor Histologic Classification","preferredDefinition":"information related to gynecologic tumor histologic classification.","longName":"GYN_TUMOR_HIST_CLASS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206690","version":"1","preferredName":"Gynecologic Neoplasm","preferredDefinition":"Of or relating to or practicing gynecology; pertaining to the health issues of women.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C28016:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynecologic","conceptCode":"C28016","definition":"Of or relating to or practicing gynecology; pertaining to the health issues of women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0016-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207691","version":"1","preferredName":"Histologic Classification","preferredDefinition":"Of or relating to histology.:Classification; the grouping of things into classes or categories.","longName":"C25526:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2C90-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E67BB287-4EBB-5127-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015349","version":"3","preferredName":"Gynecologic Tumor Histologic Category","preferredDefinition":"the structural pattern of cancer cells used to define a diagnosis.","longName":"GYN_TUMOR_HIST_CAT","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adenocarcinoma with Squamous Differentiation","valueDescription":"ADENOCARCINOMA WITH SQUAMOUS DIFFERENTIATION","ValueMeaning":{"publicId":"2558178","version":"1","preferredName":"ADENOCARCINOMA WITH SQUAMOUS DIFFERENTIATION","longName":"2558178","preferredDefinition":"ADENOCARCINOMA WITH SQUAMOUS DIFFERENTIATION","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B04F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44DC-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adenocarcinoma, unspecified","valueDescription":"Adenocarcinoma, unspecified","ValueMeaning":{"publicId":"2567183","version":"1","preferredName":"Adenocarcinoma, unspecified","longName":"2567183","preferredDefinition":"Adenocarcinoma, unspecified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"ONEDATA","dateModified":"2003-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44DE-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adenofibroma","valueDescription":"ADENOFIBROMA","ValueMeaning":{"publicId":"2558182","version":"1","preferredName":"ADENOFIBROMA","longName":"2558182","preferredDefinition":"ADENOFIBROMA","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Female Reproductive System Adenofibroma","conceptCode":"C8984","definition":"A benign or borderline neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B053-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44E0-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adenosarcoma","valueDescription":"Adenosarcoma","ValueMeaning":{"publicId":"2567182","version":"1","preferredName":"Adenosarcoma","longName":"2567182","preferredDefinition":"Adenosarcoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosarcoma","conceptCode":"C9474","definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44E2-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adenosquamous carcinoma","valueDescription":"ADENOSQUAMOUS","ValueMeaning":{"publicId":"2558185","version":"1","preferredName":"ADENOSQUAMOUS","longName":"2558185","preferredDefinition":"ADENOSQUAMOUS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B056-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44E4-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Brenner tumor (benign)","valueDescription":"BRENNER TUMOR (BENIGN)","ValueMeaning":{"publicId":"2558335","version":"1","preferredName":"BRENNER TUMOR (BENIGN)","longName":"2558335","preferredDefinition":"BRENNER TUMOR (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44E6-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Brenner tumor (malignant)","valueDescription":"Brenner tumor (malignant)","ValueMeaning":{"publicId":"2567185","version":"1","preferredName":"Brenner tumor (malignant)","longName":"2567185","preferredDefinition":"Brenner tumor (malignant)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"ONEDATA","dateModified":"2003-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44E8-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Brenner tumor of LMP","valueDescription":"BRENNER TUMOR OF LOW MALIGNANT POTENTIAL","ValueMeaning":{"publicId":"2558337","version":"1","preferredName":"BRENNER TUMOR OF LOW MALIGNANT POTENTIAL","longName":"2558337","preferredDefinition":"BRENNER TUMOR OF LOW MALIGNANT POTENTIAL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44EA-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Cancer with dermoid cyst","valueDescription":"CANCER WITH DERMOID CYST, SPECIFY TYPES","ValueMeaning":{"publicId":"2558349","version":"1","preferredName":"CANCER WITH DERMOID CYST, SPECIFY TYPES","longName":"2558349","preferredDefinition":"CANCER WITH DERMOID CYST, SPECIFY TYPES","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44EC-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Carcinosarcoma MMT","valueDescription":"Carcinosarcoma/Mesodermal (Mullerian) mixed tumor","ValueMeaning":{"publicId":"2567187","version":"1","preferredName":"Carcinosarcoma/Mesodermal (Mullerian) mixed tumor","longName":"2567187","preferredDefinition":"Carcinosarcoma/Mesodermal (Mullerian) mixed tumor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D380-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"ONEDATA","dateModified":"2003-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44EE-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Choriocarcinoma","valueDescription":"Choriocarcinoma","ValueMeaning":{"publicId":"2574079","version":"1","preferredName":"Choriocarcinoma","longName":"2574079","preferredDefinition":"An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriocarcinoma","conceptCode":"C2948","definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE6C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Added missing system generated definition for TCGA. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44F0-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"Clear cell carcinoma","valueDescription":"CLEAR CELL CARCINOMA","ValueMeaning":{"publicId":"2558510","version":"1","preferredName":"CLEAR CELL CARCINOMA","longName":"2558510","preferredDefinition":"CLEAR CELL CARCINOMA","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B19B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44F2-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Clear cell cystadenofibroma (benign)","valueDescription":"CLEAR CELL CYSTADENOFIBROMA (BENIGN)","ValueMeaning":{"publicId":"2558511","version":"1","preferredName":"CLEAR CELL CYSTADENOFIBROMA (BENIGN)","longName":"2558511","preferredDefinition":"CLEAR CELL CYSTADENOFIBROMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B19C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44F4-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Clear cell cystadenoma (benign)","valueDescription":"CLEAR CELL CYSTADENOMA (BENIGN)","ValueMeaning":{"publicId":"2558512","version":"1","preferredName":"CLEAR CELL CYSTADENOMA (BENIGN)","longName":"2558512","preferredDefinition":"CLEAR CELL CYSTADENOMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B19D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44F6-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Clear cell tumor of LMP","valueDescription":"CLEAR CELL TUMOR OF LOW MALIGNANT POTENTIAL","ValueMeaning":{"publicId":"2558513","version":"1","preferredName":"CLEAR CELL TUMOR OF LOW MALIGNANT POTENTIAL","longName":"2558513","preferredDefinition":"CLEAR CELL TUMOR OF LOW MALIGNANT POTENTIAL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B19E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44F8-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Dysgerminoma","valueDescription":"Dysgerminoma","ValueMeaning":{"publicId":"2574078","version":"1","preferredName":"Dysgerminoma","longName":"2574078","preferredDefinition":"Dysgerminoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysgerminoma","conceptCode":"C2996","definition":"A malignant germ cell tumor characterized by the presence of a monotonous primitive germ cell population.  The neoplastic cells form aggregates and have an abundant pale cytoplasm and uniform nuclei.  The aggregates of the germ cells are separated by fibrous septa which contain inflammatory cells, mostly T-lymphocytes.  It arises primarily in the ovaries, but can occur both primarily and secondarily at other sites, particularly the central nervous system.  It responds to chemotherapy and radiotherapy. Its prognosis is related to the tumor stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44FA-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Embryonal carcinoma","valueDescription":"Embryonal carcinoma","ValueMeaning":{"publicId":"2567194","version":"1","preferredName":"Embryonal carcinoma","longName":"2567194","preferredDefinition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Carcinoma","conceptCode":"C3752","definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D387-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Added missing system generated definition. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44FC-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"Endodermal sinus tumor","valueDescription":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","ValueMeaning":{"publicId":"2558716","version":"1","preferredName":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","longName":"2558716","preferredDefinition":"ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B269-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-44FE-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrial stromal sarcoma","valueDescription":"Endometrial Stromal Sarcoma","ValueMeaning":{"publicId":"2567186","version":"1","preferredName":"Endometrial Stromal Sarcoma","longName":"2567186","preferredDefinition":"A malignant, infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrial stromal sarcoma is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterized by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4500-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrioid adenocarcinoma","valueDescription":"Endometrioid adenocarcinoma","ValueMeaning":{"publicId":"2567180","version":"1","preferredName":"Endometrioid adenocarcinoma","longName":"2567180","preferredDefinition":"Endometrioid adenocarcinoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Adenocarcinoma","conceptCode":"C3769","definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D379-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4502-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrioid cystadenofibroma (benign)","valueDescription":"ENDOMETRIOID CYSTADENOFIBROMA (BENIGN)","ValueMeaning":{"publicId":"2558719","version":"1","preferredName":"ENDOMETRIOID CYSTADENOFIBROMA (BENIGN)","longName":"2558719","preferredDefinition":"ENDOMETRIOID CYSTADENOFIBROMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B26C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4504-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrioid cystadenoma (benign)","valueDescription":"ENDOMETRIOID CYSTADENOMA (BENIGN)","ValueMeaning":{"publicId":"2558720","version":"1","preferredName":"ENDOMETRIOID CYSTADENOMA (BENIGN)","longName":"2558720","preferredDefinition":"ENDOMETRIOID CYSTADENOMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B26D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4506-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrioid tumor of LMP","valueDescription":"ENDOMETRIOID TUMOR OF LOW MALIGNANT POTENTIAL","ValueMeaning":{"publicId":"2558721","version":"1","preferredName":"ENDOMETRIOID TUMOR OF LOW MALIGNANT POTENTIAL","longName":"2558721","preferredDefinition":"A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor","conceptCode":"C7983","definition":"An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B26E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4508-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Fibroma","valueDescription":"FIBROMA","ValueMeaning":{"publicId":"2558772","version":"1","preferredName":"FIBROMA","longName":"2558772","preferredDefinition":"FIBROMA","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibroma","conceptCode":"C3041","definition":"A non-metastasizing neoplasm arising from the fibrous tissue. It is characterized by the presence of spindle-shaped fibroblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2A1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-450A-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Germ cell tumor, mixed","valueDescription":"GERM CELL TUMOR, MIXED","ValueMeaning":{"publicId":"2558822","version":"1","preferredName":"GERM CELL TUMOR, MIXED","longName":"2558822","preferredDefinition":"GERM CELL TUMOR, MIXED","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2D3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-450C-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Gestational trophoblastic disease","valueDescription":"GESTATIONAL TROPHOBLASTIC DISEASE","ValueMeaning":{"publicId":"2558824","version":"1","preferredName":"GESTATIONAL TROPHOBLASTIC DISEASE","longName":"2558824","preferredDefinition":"GESTATIONAL TROPHOBLASTIC DISEASE","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2D5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-450E-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Granulosa cell tumor","valueDescription":"Granulosa Cell Tumor","ValueMeaning":{"publicId":"2567190","version":"1","preferredName":"Granulosa Cell Tumor","longName":"2567190","preferredDefinition":"A slow-growing, malignant tumor, characterize by the presence of granulosa-like cells and Call-Exner bodies, that is almost always found in the ovary. In rare cases, it has also been found in the testicle.  There are two types of granulosa cell tumor that can be distinguished under the microscope: the adult and the juvenile.  The testicular juvenile granulosa cell tumors are perhaps the most common congenital testicular neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulosa Cell Tumor","conceptCode":"C3070","definition":"A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D383-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4510-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Gynandroblastoma","valueDescription":"Gynandroblastoma","ValueMeaning":{"publicId":"2567191","version":"1","preferredName":"Gynandroblastoma","longName":"2567191","preferredDefinition":"Gynandroblastoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynandroblastoma","conceptCode":"C0018413","definition":"C56.9","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D384-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4512-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mixed epithelial carcinoma","valueDescription":"Mixed epithelial carcinoma, specify components","ValueMeaning":{"publicId":"2567188","version":"1","preferredName":"Mixed epithelial carcinoma, specify components","longName":"2567188","preferredDefinition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Seromucinous Carcinoma","conceptCode":"C40090","definition":"A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D381-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4514-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mixed malignant germ cell tumor","valueDescription":"Mixed malignant germ cell tumor, specify components","ValueMeaning":{"publicId":"2567197","version":"1","preferredName":"Mixed malignant germ cell tumor, specify components","longName":"2567197","preferredDefinition":"Mixed malignant germ cell tumor, specify components","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D38A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"ONEDATA","dateModified":"2003-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4516-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mucinous adenocarcinoma","valueDescription":"Mucinous adenocarcinoma","ValueMeaning":{"publicId":"2567179","version":"1","preferredName":"Mucinous adenocarcinoma","longName":"2567179","preferredDefinition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Adenocarcinoma","conceptCode":"C26712","definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D378-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"REEVESD","dateModified":"2013-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4518-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mucinous cystadenofibroma (benign)","valueDescription":"MUCINOUS CYSTADENOFIBROMA (BENIGN)","ValueMeaning":{"publicId":"2559284","version":"1","preferredName":"MUCINOUS CYSTADENOFIBROMA (BENIGN)","longName":"2559284","preferredDefinition":"A benign or low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Cystadenoma","conceptCode":"C2973","definition":"A benign or low malignant potential cystic epithelial neoplasm composed of cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4A1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added NCIt concept DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-451A-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mucinous cystadenoma (benign)","valueDescription":"MUCINOUS CYSTADENOMA (BENIGN)","ValueMeaning":{"publicId":"2559285","version":"1","preferredName":"MUCINOUS CYSTADENOMA (BENIGN)","longName":"2559285","preferredDefinition":"MUCINOUS CYSTADENOMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4A2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-451C-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mucinous tumor of LMP","valueDescription":"MUCINOUS TUMOR OF LOW MALIGNANT POTENTIAL","ValueMeaning":{"publicId":"2559287","version":"1","preferredName":"MUCINOUS TUMOR OF LOW MALIGNANT POTENTIAL","longName":"2559287","preferredDefinition":"MUCINOUS TUMOR OF LOW MALIGNANT POTENTIAL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-451E-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other specify","valueDescription":"Other specify","ValueMeaning":{"publicId":"2570538","version":"1","preferredName":"Other specify","longName":"2570538","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E097-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2023-11-17","changeDescription":"Associated concept to VM for TCGA. mc 11/9/12 - reversed concept order to match the semantics of this phrase which is \"other\" with \"specify\" as a qualifier/modifier - DW 12-30-2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4520-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Ovarian endometriosis","valueDescription":"OVARIAN ENDOMETRIOSIS","ValueMeaning":{"publicId":"2559680","version":"1","preferredName":"OVARIAN ENDOMETRIOSIS","longName":"2559680","preferredDefinition":"OVARIAN ENDOMETRIOSIS","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Endometriosis","conceptCode":"C27628","definition":"A non-neoplastic disorder characterized by the growth of endometrial tissue in the ovaries.  It results in the development of blood filled ovarian cysts (chocolate cysts), and creation of scars and adhesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B62D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4522-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Physiologic cyst (corpus luteum)","valueDescription":"PHYSIOLOGIC CYST (CORPUS LUTEUM)","ValueMeaning":{"publicId":"2559806","version":"1","preferredName":"PHYSIOLOGIC CYST (CORPUS LUTEUM)","longName":"2559806","preferredDefinition":"PHYSIOLOGIC CYST (CORPUS LUTEUM)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6AB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4524-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Physiologic cyst (follicle)","valueDescription":"PHYSIOLOGIC CYST (FOLLICLE)","ValueMeaning":{"publicId":"2559807","version":"1","preferredName":"PHYSIOLOGIC CYST (FOLLICLE)","longName":"2559807","preferredDefinition":"PHYSIOLOGIC CYST (FOLLICLE)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6AC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4526-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Polyembryoma","valueDescription":"POLYEMBRYOMA","ValueMeaning":{"publicId":"2559823","version":"1","preferredName":"POLYEMBRYOMA","longName":"2559823","preferredDefinition":"POLYEMBRYOMA","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyembryoma","conceptCode":"C0334518","definition":"Definition not available.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4528-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Serous adenocarcinoma","valueDescription":"Serous adenocarcinoma","ValueMeaning":{"publicId":"2567199","version":"1","preferredName":"Serous adenocarcinoma","longName":"2567199","preferredDefinition":"Serous adenocarcinoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous Adenocarcinoma","conceptCode":"C40101","definition":"An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present.  Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D38C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-452A-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Serous cystadenofibroma (benign)","valueDescription":"SEROUS CYSTADENOFIBROMA (BENIGN)","ValueMeaning":{"publicId":"2560030","version":"1","preferredName":"SEROUS CYSTADENOFIBROMA (BENIGN)","longName":"2560030","preferredDefinition":"SEROUS CYSTADENOFIBROMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B78B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-452C-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Serous cystadenoma (benign)","valueDescription":"SEROUS CYSTADENOMA (BENIGN)","ValueMeaning":{"publicId":"2560031","version":"1","preferredName":"SEROUS CYSTADENOMA (BENIGN)","longName":"2560031","preferredDefinition":"SEROUS CYSTADENOMA (BENIGN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B78C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-452E-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Serous tumor of LMP","valueDescription":"SEROUS TUMOR OF LOW MALIGNANT POTENTIAL","ValueMeaning":{"publicId":"2560032","version":"1","preferredName":"SEROUS TUMOR OF LOW MALIGNANT POTENTIAL","longName":"2560032","preferredDefinition":"A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma","conceptCode":"C122585","definition":"A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B78D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"DWARZEL","dateModified":"2019-03-21","changeDescription":"Added concept, verified with EVS team - DW 03-21-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4530-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Sertoli-Leydig cell (Androblastoma)","valueDescription":"SERTOLI-LEYDIG CELL (ANDROBLASTOMA)","ValueMeaning":{"publicId":"2560033","version":"1","preferredName":"SERTOLI-LEYDIG CELL (ANDROBLASTOMA)","longName":"2560033","preferredDefinition":"SERTOLI-LEYDIG CELL (ANDROBLASTOMA)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B78E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4532-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"REBOYJ","dateModified":"2012-12-28","deletedIndicator":"No"},{"value":"Sex-cord/stromal, unclassified","valueDescription":"Sex-cord/stromal, unclassified","ValueMeaning":{"publicId":"2567192","version":"1","preferredName":"Sex-cord/stromal, unclassified","longName":"2567192","preferredDefinition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sex Cord-Stromal Tumor","conceptCode":"C3794","definition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D385-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code - DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4534-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Simple cyst","valueDescription":"SIMPLE CYST","ValueMeaning":{"publicId":"2560052","version":"1","preferredName":"SIMPLE CYST","longName":"2560052","preferredDefinition":"SIMPLE CYST","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7A1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4536-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Squamous cell carcinoma","valueDescription":"Squamous cell carcinoma","ValueMeaning":{"publicId":"2574081","version":"1","preferredName":"Squamous cell carcinoma","longName":"2574081","preferredDefinition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE6E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"REEVESD","dateModified":"2016-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4538-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"Steroid/Lipid cell tumor","valueDescription":"STEROID/LIPID CELL TUMOR","ValueMeaning":{"publicId":"2560106","version":"1","preferredName":"STEROID/LIPID CELL TUMOR","longName":"2560106","preferredDefinition":"STEROID/LIPID CELL TUMOR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-453A-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Teratoma, immature","valueDescription":"TERATOMA, IMMATURE, SPECIFY COMPONENTS","ValueMeaning":{"publicId":"2560188","version":"1","preferredName":"TERATOMA, IMMATURE, SPECIFY COMPONENTS","longName":"2560188","preferredDefinition":"TERATOMA, IMMATURE, SPECIFY COMPONENTS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B829-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-453C-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Teratoma, mature","valueDescription":"Teratoma, mature","ValueMeaning":{"publicId":"2567196","version":"1","preferredName":"Teratoma, mature","longName":"2567196","preferredDefinition":"Teratoma, mature","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D389-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"ONEDATA","dateModified":"2003-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-453E-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"Transitional cell carcinoma (including Brenner)","valueDescription":"TRANSITIONAL CELL CARCINOMA, INCLUDING BRENNER TUMOR","ValueMeaning":{"publicId":"2560304","version":"1","preferredName":"TRANSITIONAL CELL CARCINOMA, INCLUDING BRENNER TUMOR","longName":"2560304","preferredDefinition":"TRANSITIONAL CELL CARCINOMA, INCLUDING BRENNER TUMOR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B89D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4540-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Undifferentiated carcinoma","valueDescription":"Undifferentiated carcinoma","ValueMeaning":{"publicId":"2567189","version":"1","preferredName":"Undifferentiated carcinoma","longName":"2567189","preferredDefinition":"Undifferentiated carcinoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D382-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4542-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Small cell carcinoma","valueDescription":"Small cell carcinoma","ValueMeaning":{"publicId":"2567204","version":"1","preferredName":"Small cell carcinoma","longName":"2567204","preferredDefinition":"A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble \"oat cells\" under the microscope.  Small cell carcinoma most often affects the lungs.  Clinically, this is often a rapidly growing cancer that spreads to distant sites early.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Cell Neuroendocrine Carcinoma","conceptCode":"C3915","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D391-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"REEVESD","dateModified":"2016-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4544-2374-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"Normal Tissue","valueDescription":"NORMAL TISSUE","ValueMeaning":{"publicId":"2559584","version":"1","preferredName":"NORMAL TISSUE","longName":"2559584","preferredDefinition":"An anatomical structure, which consists of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships. Examples: epithelium, muscle tissue, connective tissue, neural tissue, lymphoid tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Normal Tissue","conceptCode":"C33177","definition":"An anatomical structure, which consists of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships. Examples: epithelium, muscle tissue, connective tissue, neural tissue, lymphoid tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5CD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SOKKERL","dateModified":"2019-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4548-2374-E034-0003BA12F5E7","beginDate":"2002-10-01","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Villoglandular carcinoma","valueDescription":"VILLOGLANDULAR CARCINOMA","ValueMeaning":{"publicId":"2562494","version":"1","preferredName":"VILLOGLANDULAR CARCINOMA","longName":"2562494","preferredDefinition":"Villoglandular carcinoma ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C12B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-01","endDate":null,"createdBy":"PWEST","dateCreated":"2002-10-01","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-454A-2374-E034-0003BA12F5E7","beginDate":"2002-10-01","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Benign NOS","valueDescription":"Benign","ValueMeaning":{"publicId":"2558281","version":"1","preferredName":"Benign","longName":"2558281","preferredDefinition":"(beh-NINE) Not cancerous; does not invade nearby tissue or spread to other parts of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign","conceptCode":"C14172","definition":"For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2013-10-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-454C-2374-E034-0003BA12F5E7","beginDate":"2002-10-01","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leiomyosarcoma","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"2562491","version":"1","preferredName":"Leiomyosarcoma","longName":"2562491","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C128-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2002-09-27","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BAF982D9-4546-2374-E034-0003BA12F5E7","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Endometrial carcinoma","valueDescription":"Endometrial carcinoma","ValueMeaning":{"publicId":"2761246","version":"1","preferredName":"Endometrial carcinoma","longName":"2761246","preferredDefinition":"Endometrial carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"509340F1-7F6E-294D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5093461B-4F32-25F6-E044-0003BA3F9857","beginDate":"2008-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-06-26","modifiedBy":"ONEDATA","dateModified":"2008-06-26","deletedIndicator":"No"},{"value":"Uterine carcinosarcoma","valueDescription":"Uterine carcinosarcoma","ValueMeaning":{"publicId":"2761247","version":"1","preferredName":"Uterine carcinosarcoma","longName":"2761247","preferredDefinition":"Uterine carcinosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"509340F1-7F7E-294D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5093461B-4F44-25F6-E044-0003BA3F9857","beginDate":"2008-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2008-06-26","modifiedBy":"ONEDATA","dateModified":"2008-06-26","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A645F68-7346-5BA1-E040-BB89AD436D88","beginDate":"2009-12-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-10","modifiedBy":"ONEDATA","dateModified":"2009-12-10","deletedIndicator":"No"},{"value":"Uterine leiomyosarcoma","valueDescription":"Uterine leiomyosarcoma","ValueMeaning":{"publicId":"2568851","version":"1","preferredName":"Uterine leiomyosarcoma","longName":"2568851","preferredDefinition":"Uterine leiomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DA00-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89BB452F-C94A-91E7-E040-BB89AD4344ED","beginDate":"2008-06-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-23","modifiedBy":"ONEDATA","dateModified":"2010-06-23","deletedIndicator":"No"},{"value":"Unclassified carcinoma","valueDescription":"Unclassified Carcinoma","ValueMeaning":{"publicId":"3120329","version":"1","preferredName":"Unclassified Carcinoma","longName":"3120329","preferredDefinition":"Not arranged or included in any specific grouping.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unclassified","conceptCode":"C64486","definition":"Not arranged or included in any specific grouping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2A88-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AEE1D01-2AA1-F246-E040-BB89AD433010","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"ONEDATA","dateModified":"2010-07-09","deletedIndicator":"No"},{"value":"Other carcinoma","valueDescription":"Other Carcinoma","ValueMeaning":{"publicId":"3120330","version":"1","preferredName":"Other Carcinoma","longName":"3120330","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2AAE-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AEE1D01-2AC7-F246-E040-BB89AD433010","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"ONEDATA","dateModified":"2010-07-09","deletedIndicator":"No"},{"value":"Malignant Brenner's tumor","valueDescription":"Malignant Ovarian Brenner Tumor","ValueMeaning":{"publicId":"3120341","version":"1","preferredName":"Malignant Ovarian Brenner Tumor","longName":"3120341","preferredDefinition":"A Brenner tumor of the ovary characterized by a cytologically malignant cell population and stromal invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Brenner Tumor","conceptCode":"C4270","definition":"A malignant neoplasm that arises from the ovary. It is characterized by the presence of an invasive malignant urothelial-type cellular component and nests of benign urothelial-type cells in a fibrotic stroma. When the neoplasm is confined to the ovary, the prognosis is good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AEE1D01-2AD5-F246-E040-BB89AD433010","latestVersionIndicator":"Yes","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AEE1D01-2AEE-F246-E040-BB89AD433010","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"ONEDATA","dateModified":"2010-07-09","deletedIndicator":"No"},{"value":"Adenocarcinoma, NOS","valueDescription":"Not Otherwise Specified Adenocarcinoma","ValueMeaning":{"publicId":"2861284","version":"1","preferredName":"Not Otherwise Specified Adenocarcinoma","longName":"2861284","preferredDefinition":"Not characterized in any other way.: carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67ACCB6B-ECC3-FC03-E040-BB89AD4318C7","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AEE1D01-2B02-F246-E040-BB89AD433010","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"ONEDATA","dateModified":"2010-07-09","deletedIndicator":"No"},{"value":"Transitional Cell Carcinoma","valueDescription":"Transitional Cell Carcinoma","ValueMeaning":{"publicId":"2560303","version":"1","preferredName":"Transitional Cell Carcinoma","longName":"2560303","preferredDefinition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Cell Carcinoma","conceptCode":"C2930","definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B89C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2016-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AEE1D01-2B17-F246-E040-BB89AD433010","beginDate":"2010-07-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-09","modifiedBy":"ONEDATA","dateModified":"2010-07-09","deletedIndicator":"No"},{"value":"Clear cell adenocarcinoma","valueDescription":"Clear Cell Adenocarcinoma","ValueMeaning":{"publicId":"3081856","version":"1","preferredName":"Clear Cell Adenocarcinoma","longName":"3081856","preferredDefinition":"(kar-sin-O-ma) A rare type of tumor of the female genital tract in which the inside of the cells looks clear when viewed under a microscope.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Adenocarcinoma","conceptCode":"C3766","definition":"A malignant neoplasm composed of glandular epithelial clear cells.  Various architectural patterns may be seen, including papillary, tubulocystic, and solid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85BDDDAE-472C-1D2D-E040-BB89AD436AC9","latestVersionIndicator":"Yes","beginDate":"2010-05-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD403DE6-0CB3-E944-E040-BB89AD435C96","beginDate":"2012-04-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-04-09","modifiedBy":"ONEDATA","dateModified":"2012-04-09","deletedIndicator":"No"},{"value":"Verrucous Carcinoma","valueDescription":"Verrucous squamous cell carcinoma","ValueMeaning":{"publicId":"2567899","version":"1","preferredName":"Verrucous squamous cell carcinoma","longName":"2567899","preferredDefinition":"Verrucous squamous cell carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-02","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F8B3-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma, in situ","valueDescription":"Squamous Cell Carcinoma, in situ","ValueMeaning":{"publicId":"3346877","version":"1","preferredName":"Squamous Cell Carcinoma, in situ","longName":"3346877","preferredDefinition":"Squamous Cell Carcinoma, in situ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61EBCA6-F8BD-5FA8-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F8D6-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Sarcoma, unspecified","valueDescription":"Sarcoma","ValueMeaning":{"publicId":"2574579","version":"1","preferredName":"Sarcoma","longName":"2574579","preferredDefinition":"A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F060-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"REEVESD","dateModified":"2006-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F8EA-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Sarcoma, other","valueDescription":"Sarcoma NOS","ValueMeaning":{"publicId":"3155794","version":"1","preferredName":"Sarcoma NOS","longName":"3155794","preferredDefinition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"942FF03C-0577-584B-E040-BB89AD4324F7","latestVersionIndicator":"Yes","beginDate":"2010-11-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-11-03","modifiedBy":"DWARZEL","dateModified":"2019-03-21","changeDescription":"Added concept DW 03-21-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F8FE-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Rhabdomyosarcoma, Embryonal","valueDescription":"Stratum 4: Rhabdomyosarcoma","ValueMeaning":{"publicId":"2574678","version":"1","preferredName":"Stratum 4: Rhabdomyosarcoma","longName":"2574678","preferredDefinition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F0C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-01","modifiedBy":"CAMPBELB","dateModified":"2013-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F912-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Paget's Disease","valueDescription":"Paget's Disease","ValueMeaning":{"publicId":"3251708","version":"1","preferredName":"Paget's Disease","longName":"3251708","preferredDefinition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget's cell neoplasms include Paget's disease of the nipple and extramammary Paget's disease which may affect the vulva, penis, anus, skin and scrotum. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paget Disease","conceptCode":"C7073","definition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7696A98-D61A-85AE-E040-BB89AD433885","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F91C-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Neuroendocrine Tumor","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2559503","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"2559503","preferredDefinition":"A malignant neuroendocrine tumor composed of cells containing secretory granules that stain positive for NSE and chromogranin.  Tumor cells are often round and form clusters or trabecular sheets.  Representative examples are carcinoid tumor, small cell carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F930-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Metaplasia","valueDescription":"Metaplasia","ValueMeaning":{"publicId":"2838903","version":"1","preferredName":"Metaplasia","longName":"2838903","preferredDefinition":"Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaplasia","conceptCode":"C3236","definition":"Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A521-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F93A-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Mesonephric Carcinoma","valueDescription":"Mesonephric Carcinoma","ValueMeaning":{"publicId":"3346878","version":"1","preferredName":"Mesonephric Carcinoma","longName":"3346878","preferredDefinition":"Mesonephric Carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61EBCA6-F944-5FA8-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F95D-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2567413","version":"1","preferredName":"Melanoma","longName":"2567413","preferredDefinition":"A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D462-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F967-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Lymphomas, Malignant","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2567355","version":"1","preferredName":"Lymphoma","longName":"2567355","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D428-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F97B-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Leiomyoma","valueDescription":"Leiomyoma","ValueMeaning":{"publicId":"2572962","version":"1","preferredName":"Leiomyoma","longName":"2572962","preferredDefinition":"Leiomyoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"MAESKEB","dateModified":"2005-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F985-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Large Cell Carcinoma","valueDescription":"Large cell carcinoma","ValueMeaning":{"publicId":"2567205","version":"1","preferredName":"Large cell carcinoma","longName":"2567205","preferredDefinition":"Large cell carcinoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D392-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F999-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Invasive Squamous Cell Carcinoma","valueDescription":"Squamous cell carcinoma, invasive","ValueMeaning":{"publicId":"3243061","version":"1","preferredName":"Squamous cell carcinoma, invasive","longName":"3243061","preferredDefinition":"Squamous cell carcinoma, invasive","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A537147F-3935-B22A-E040-BB89AD430A3F","latestVersionIndicator":"Yes","beginDate":"2011-06-08","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F9AD-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Hydatidiform Mole","valueDescription":"Hydatidiform Mole","ValueMeaning":{"publicId":"3211157","version":"1","preferredName":"Hydatidiform Mole","longName":"3211157","preferredDefinition":"A gestational disorder characterized by an abnormal placenta with marked enlargement of the chorionic villi and hyperplasia of the villous trophoblastic cells.  According to the amount of villous involvement, a hydatidiform mole is defined as complete or partial.  Most molar pregnancies are complete and are characterized by generalized hydropic villous changes.  Partial moles are characterized by a mixture of large hydropic villi and normal placenta tissue.  Complete moles are usually diploid and typically present between the eleventh and twenty-fifth week of pregnancy, whereas partial moles are usually triploid and usually present around the nineteenth week of pregnancy.  The incidence of choriocarcinoma is higher in patients with complete hydatidiform mole.  When a hydatidiform mole invades the myometrium and broad ligament, or it is found in distant sites as vagina, vulva, and lung, it is referred as invasive mole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydatidiform Mole","conceptCode":"C3110","definition":"A gestational trophoblastic disorder characterized by marked enlargement of the chorionic villi, hyperplasia of the villous trophoblastic cells and hydropic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D5F0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F9B7-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Glassy Cell Carcinoma","valueDescription":"8015-3 Glassy cell carcinoma","ValueMeaning":{"publicId":"2564131","version":"1","preferredName":"8015-3 Glassy cell carcinoma","longName":"2564131","preferredDefinition":"Glassy cell carcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C790-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"JASUR","dateCreated":"2003-01-27","modifiedBy":"ONEDATA","dateModified":"2003-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F9CB-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Endometrial Stromal Sarcoma, Low Grade","valueDescription":"Endometrial Stromal Sarcoma","ValueMeaning":{"publicId":"2567186","version":"1","preferredName":"Endometrial Stromal Sarcoma","longName":"2567186","preferredDefinition":"A malignant, infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrial stromal sarcoma is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterized by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F9E0-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Endometrial Stromal Sarcoma, High Grade","valueDescription":"Endometrial Stromal Sarcoma","ValueMeaning":{"publicId":"2567186","version":"1","preferredName":"Endometrial Stromal Sarcoma","longName":"2567186","preferredDefinition":"A malignant, infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrial stromal sarcoma is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterized by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-F9F4-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Dysplasia, Severe","valueDescription":"Dysplasia","ValueMeaning":{"publicId":"2838899","version":"1","preferredName":"Dysplasia","longName":"2838899","preferredDefinition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns.  The cellular changes include nuclear and cytoplasmic abnormalities.  Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplasia","conceptCode":"C4086","definition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A4B7-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA08-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Dysplasia, Moderate","valueDescription":"Dysplasia","ValueMeaning":{"publicId":"2838899","version":"1","preferredName":"Dysplasia","longName":"2838899","preferredDefinition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns.  The cellular changes include nuclear and cytoplasmic abnormalities.  Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplasia","conceptCode":"C4086","definition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A4B7-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA1C-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Dysplasia, Mild","valueDescription":"Dysplasia","ValueMeaning":{"publicId":"2838899","version":"1","preferredName":"Dysplasia","longName":"2838899","preferredDefinition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns.  The cellular changes include nuclear and cytoplasmic abnormalities.  Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplasia","conceptCode":"C4086","definition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A4B7-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA30-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Carcinosarcoma-homologous","valueDescription":"Carcinosarcoma - homologous","ValueMeaning":{"publicId":"3178991","version":"1","preferredName":"Carcinosarcoma - homologous","longName":"3178991","preferredDefinition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Carcinosarcoma, Homologous Type","conceptCode":"C113238","definition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4A88-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"DWARZEL","dateModified":"2019-06-20","changeDescription":"Added concept DW -6-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA44-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Carcinosarcoma-heterologous","valueDescription":"Carcinosarcoma - heterologous","ValueMeaning":{"publicId":"3178990","version":"1","preferredName":"Carcinosarcoma - heterologous","longName":"3178990","preferredDefinition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Carcinosarcoma, Heterologous Type","conceptCode":"C113239","definition":"A carcinosarcoma of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4A65-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA58-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Carcinosarcoma, unspecified","valueDescription":"Carcinosarcoma, type unspecified","ValueMeaning":{"publicId":"3185164","version":"1","preferredName":"Carcinosarcoma, type unspecified","longName":"3185164","preferredDefinition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinosarcoma","conceptCode":"C34448","definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A5034CF-29F9-DD89-E040-BB89AD436D64","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"DWARZEL","dateModified":"2019-06-20","changeDescription":"Add concept code  per EVS recommendation of which concept to use - DW 06202019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA6C-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Basal Cell Carcinoma","valueDescription":"Basal Cell Carcinoma","ValueMeaning":{"publicId":"2567411","version":"1","preferredName":"Basal Cell Carcinoma","longName":"2567411","preferredDefinition":"(BAY-sal sel kar-sin-O-ma) A type of skin cancer that arises from the basal cells, small round cells found in the lower part (or base) of the epidermis, the outer layer of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basal Cell Carcinoma","conceptCode":"CL066969","definition":"Basal cell carcinoma is the most frequently seen skin cancer.  It arises from basal cells of the epidermis and pilosebaceous units.  Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities.  Basal cell carcinoma usually grows in a slow and indolent fashion.  However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone.  Distant metastases are rare.  Excision, curettage and  irradiation cure most basal cell carcinomas. --2002","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D460-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA76-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Adenoid Cystic Carcinoma","valueDescription":"Adenoid cystic carcinoma","ValueMeaning":{"publicId":"2567905","version":"1","preferredName":"Adenoid cystic carcinoma","longName":"2567905","preferredDefinition":"A malignant tumor arising from the epithelial cells. Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma). Adenoid cystic carcinomas mostly occur in the salivary glands. Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs. Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur. Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D64E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-02","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FA80-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Adenocarcinoma, in situ","valueDescription":"Adenocarcinoma, in situ","ValueMeaning":{"publicId":"3346879","version":"1","preferredName":"Adenocarcinoma, in situ","longName":"3346879","preferredDefinition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma In Situ","conceptCode":"C4123","definition":"A lesion in which the normally situated glands are partially or completely replaced by atypical cells with malignant characteristics.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B61EBCA6-FA8A-5FA8-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"DWARZEL","dateModified":"2019-03-20","changeDescription":"Added concept code DW 03-20-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B61EBCA6-FAA3-5FA8-E040-BB89AD436C77","beginDate":"2012-01-09","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-09","modifiedBy":"ONEDATA","dateModified":"2012-01-09","deletedIndicator":"No"},{"value":"Villoglandular Adenocarcinoma","valueDescription":"Villoglandular Adenocarcinoma","ValueMeaning":{"publicId":"3361420","version":"1","preferredName":"Villoglandular Adenocarcinoma","longName":"3361420","preferredDefinition":"Villoglandular Adenocarcinoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B735CC50-9F51-D1FB-E040-BB89AD4325F2","latestVersionIndicator":"Yes","beginDate":"2012-01-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B735CC50-9F6A-D1FB-E040-BB89AD4325F2","beginDate":"2012-01-23","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-23","modifiedBy":"ONEDATA","dateModified":"2012-01-23","deletedIndicator":"No"},{"value":"Sex cord tumor with annular tubules","valueDescription":"Ovarian Sex Cord Tumor with Annular Tubules","ValueMeaning":{"publicId":"3645969","version":"1","preferredName":"Ovarian Sex Cord Tumor with Annular Tubules","longName":"3645969","preferredDefinition":"An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Sex Cord Tumor with Annular Tubules","conceptCode":"C4208","definition":"An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D125E9B5-B34E-9FE5-E040-BB89AD43258F","latestVersionIndicator":"Yes","beginDate":"2012-12-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D125E9B5-B367-9FE5-E040-BB89AD43258F","beginDate":"2012-12-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-18","modifiedBy":"ONEDATA","dateModified":"2012-12-18","deletedIndicator":"No"},{"value":"Granulosa cell-theca cell tumor","valueDescription":"Granulosa Cell-Theca Cell Tumor","ValueMeaning":{"publicId":"3645971","version":"1","preferredName":"Granulosa Cell-Theca Cell Tumor","longName":"3645971","preferredDefinition":"A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulosa Cell-Theca Cell Tumor","conceptCode":"C66751","definition":"A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D125E9B5-B374-9FE5-E040-BB89AD43258F","latestVersionIndicator":"Yes","beginDate":"2012-12-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D125E9B5-B38D-9FE5-E040-BB89AD43258F","beginDate":"2012-12-18","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-12-18","modifiedBy":"ONEDATA","dateModified":"2012-12-18","deletedIndicator":"No"},{"value":"Sclerosing Stromal Tumor","valueDescription":"Ovarian Sclerosing Stromal Tumor","ValueMeaning":{"publicId":"3252148","version":"1","preferredName":"Ovarian Sclerosing Stromal Tumor","longName":"3252148","preferredDefinition":"A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Sclerosing Stromal Tumor","conceptCode":"C4204","definition":"A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A780BB5C-C574-2B3B-E040-BB89AD43162E","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E29E3CB-E0FB-8112-E050-BB89AD432902","beginDate":"2015-08-25","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-25","modifiedBy":"ONEDATA","dateModified":"2015-08-25","deletedIndicator":"No"},{"value":"Sertoli Cell Tumor","valueDescription":"Sertoli Cell Tumor","ValueMeaning":{"publicId":"3252068","version":"1","preferredName":"Sertoli Cell Tumor","longName":"3252068","preferredDefinition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome. In males, the presenting symptom is a slow growing testicular mass. Most cases follow a benign clinical course. In females it may present with estrogenic or androgenic manifestations. The vast majority of cases have a benign clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sertoli Cell Tumor","conceptCode":"C39976","definition":"A sex cord-stromal tumor of the testis or the ovary. It is characterized by the presence of Sertoli cells forming tubules. Leydig cells are rare or absent. It may be associated with Peutz-Jeghers syndrome. In males, the presenting symptom is a slow growing testicular mass. Most cases follow a benign clinical course. In females it may present with estrogenic or androgenic manifestations. The vast majority of cases have a benign clinical course.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A780BB5C-C02D-2B3B-E040-BB89AD43162E","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E29E3CB-E125-8112-E050-BB89AD432902","beginDate":"2015-08-25","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-25","modifiedBy":"ONEDATA","dateModified":"2015-08-25","deletedIndicator":"No"},{"value":"Undifferentiated adenocarcinoma","valueDescription":"Undifferentiated Adenocarcinoma","ValueMeaning":{"publicId":"4264976","version":"1","preferredName":"Undifferentiated Adenocarcinoma","longName":"4264976","preferredDefinition":"A term used to describe cells or tissues that do not have specialized (\"mature\") structures or functions. Undifferentiated cancer cells often grow and spread quickly.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated","conceptCode":"C14176","definition":"Describes tumor cells that generally have lost all of the appearance of normal cells. They tend to grow and spread quickly and aggressively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3CF3-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"32936C88-8D06-BF10-E050-BB89AD436D35","beginDate":"2016-05-11","endDate":null,"createdBy":"BRETTS","dateCreated":"2016-05-11","modifiedBy":"ONEDATA","dateModified":"2016-05-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208105","version":"1","preferredName":"Histologic Category","preferredDefinition":"Of or relating to histology.:Category; used informally to mean a class of things.","longName":"C25526:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3D9A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAF982D9-44D9-2374-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-10","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"BRETTS","dateModified":"2016-05-11","changeDescription":"revised and updated for ISO compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811817","version":"1","longName":"Primary Cervical","context":"CTEP"},{"publicId":"2811818","version":"1","longName":"Primary Endometrial","context":"CTEP"},{"publicId":"2811819","version":"1","longName":"Primary Ovarian","context":"CTEP"},{"publicId":"2811934","version":"1","longName":"Pathology Gyn","context":"CTEP"},{"publicId":"2811938","version":"1","longName":"Recurrent Gyn","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000164","version":"1","longName":"GOG-0273","context":"NRG"},{"publicId":"10000165","version":"1","longName":"GOG-0273","context":"NRG"},{"publicId":"4104919","version":"1","longName":"GOG-0273","context":"NRG"},{"publicId":"10000172","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104913","version":"1","longName":"GOG-0241","context":"NRG"},{"publicId":"4104896","version":"1","longName":"GOG-0249","context":"NRG"},{"publicId":"4104894","version":"1","longName":"GOG-0231D","context":"NRG"},{"publicId":"10000593","version":"1","longName":"GOG-0212","context":"NRG"},{"publicId":"4104908","version":"1","longName":"GOG-0212","context":"NRG"},{"publicId":"10000594","version":"1","longName":"GOG-0212","context":"NRG"},{"publicId":"10000421","version":"1","longName":"GOG-0225","context":"NRG"},{"publicId":"10000422","version":"1","longName":"GOG-0225","context":"NRG"},{"publicId":"4104911","version":"1","longName":"GOG-0225","context":"NRG"},{"publicId":"4104888","version":"1","longName":"GOG-0209","context":"NRG"},{"publicId":"4104883","version":"1","longName":"GOG-0240","context":"NRG"},{"publicId":"4104897","version":"1","longName":"GOG-0250","context":"NRG"},{"publicId":"4104884","version":"1","longName":"GOG-0244","context":"NRG"},{"publicId":"10000341","version":"1","longName":"GOG-0244","context":"NRG"},{"publicId":"10000340","version":"1","longName":"GOG-0244","context":"NRG"},{"publicId":"10000284","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"10000285","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"4104912","version":"1","longName":"GOG-0235","context":"NRG"},{"publicId":"10000287","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104909","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"10000288","version":"1","longName":"GOG-0213","context":"NRG"},{"publicId":"4104879","version":"1","longName":"GOG-0219","context":"NRG"},{"publicId":"4104910","version":"1","longName":"GOG-0218","context":"NRG"},{"publicId":"10000080","version":"1","longName":"GOG-0218","context":"NRG"},{"publicId":"10000079","version":"1","longName":"GOG-0218","context":"NRG"},{"publicId":"10000281","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"10000282","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104929","version":"1","longName":"GOG-0280","context":"NRG"},{"publicId":"4104916","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000500","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"10000499","version":"1","longName":"GOG-0257","context":"NRG"},{"publicId":"4104898","version":"1","longName":"GOG-0258","context":"NRG"},{"publicId":"4104899","version":"1","longName":"GOG-0261","context":"NRG"},{"publicId":"4104915","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"10000592","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"10000591","version":"1","longName":"GOG-0255","context":"NRG"},{"publicId":"4058120","version":"1","longName":"GOG-0278","context":"NRG"},{"publicId":"10000590","version":"1","longName":"GOG-0252","context":"NRG"},{"publicId":"10000589","version":"1","longName":"GOG-0252","context":"NRG"},{"publicId":"4104914","version":"1","longName":"GOG-0252","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"4104885","version":"1","longName":"GOG-0263","context":"NRG"},{"publicId":"4104900","version":"1","longName":"GOG-0277","context":"NRG"},{"publicId":"4104939","version":"1","longName":"GOG-0264","context":"NRG"},{"publicId":"4104996","version":"1","longName":"GOG-0279","context":"NRG"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"GYN_TUMOR_HIST_CAT","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"COMMENT_360","type":"COMMENT","description":"Instructions on template form (to use with field 3 times): Epithelial-Stromal, Sex-cord Stromal, Germ cell","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"What is the cell type","url":null,"context":"CTEP"},{"name":"Histologic Type","type":"Preferred Question Text","description":"Histologic Type","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Type of Tumor","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BAFA7CFC-11B5-241D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-10","endDate":null,"createdBy":"PWEST","dateCreated":"2003-04-10","modifiedBy":"WONGW","dateModified":"2015-08-27","changeDescription":"revised and updated for ISO compliance; previous version had VD with no values","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}